Vertex Pharmaceuticals Incorporated
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of aā¦ read more
Healthcare
Biotechnology
35 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$514.56
Price-1.26%
-$6.56
1Y
Price
Market Cap
$130.598b
Large
Price/Earnings 3y Avg5y Avg
27x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+41.8%
EBITDA Margin+33.0%
Net Profit Margin+30.4%
Free Cash Flow Margin+41.8%
EBITDA Margin+33.0%
Net Profit Margin+30.4%
Free Cash Flow MarginRevenue
$12.624b
+4.6%
1y CAGR+8.6%
3y CAGR+9.1%
5y CAGREarnings
$4.405b
+11.4%
1y CAGR+244.9%
3y CAGR+185.9%
5y CAGREPS
$17.18
+12.1%
1y CAGR+244.6%
3y CAGR+185.5%
5y CAGRBook Value
$20.248b
$27.423b
Assets$7.175b
Liabilities$1.978b
DebtDebt to Assets
7.2%
0.4x
Debt to EBITDAFree Cash Flow
$3.796b
+18.9%
1y CAGR+133.0%
3y CAGR+95.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company